I have a questions for everyone here. We are now

I have a questions for everyone here. We are now extending to 42 days for mortality, right? Don't we already count those 195 patients with respect for those on the placebo of course, but those that are on Leronlimab arm all ready qualified in the 195, isn't it just 14 more days til they reach 42 days? So, the main question is, after 63 more patients are enrolled and we go the full 42 days after injection for them, and supposing that we have great mortality on them as well as those that will reach 42 days after having the DSMC already looked at how many have survived to 28 days and also in 10 more days they too will have reached 42.

This could tell us a bunch of them, if true of course, have obtained mortality to easily reach statistical significance and clinical significance with a much better N value and power? Just thinking out loud but to me it makes sense. If I am going about this wrong, please correct my analysis.

I guess we will find out when the 75% interim is done - GLTA

HCIT

https://media.gettyimages.com/photos/the-grea...wdoE_swYM=